Health Catalyst Files Routine 8-K on Jan 8, 2024

Ticker: HCAT · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1636422

Health Catalyst, Inc. 8-K Filing Summary
FieldDetail
CompanyHealth Catalyst, Inc. (HCAT)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $25 m
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, administrative, other-events

TL;DR

**Health Catalyst filed a routine 8-K; no major news here.**

AI Summary

Health Catalyst, Inc. filed an 8-K on January 8, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing primarily serves to update the public record regarding the company's current information, including its business address at 10897 South River Front Parkway, #300, South Jordan, UT 84095. For investors, this filing is a routine update and doesn't signal any immediate operational or financial changes, meaning it's unlikely to directly impact stock price or investment decisions.

Why It Matters

This filing is a standard procedural update, confirming basic company information. It does not contain new material financial or operational news that would typically move the stock.

Risk Assessment

Risk Level: low — This 8-K is a standard administrative filing and does not introduce new financial or operational risks.

Analyst Insight

A smart investor would recognize this as a routine administrative filing with no immediate impact on the company's fundamentals or stock price, and would not take any specific action based solely on this 8-K.

Key Players & Entities

  • Health Catalyst, Inc. (company) — the registrant filing the 8-K
  • 001-38993 (other) — Commission File Number for Health Catalyst, Inc.
  • 45-3337483 (other) — IRS Employer Identification No. for Health Catalyst, Inc.
  • 10897 South River Front Parkway, #300, South Jordan, UT 84095 (other) — principal executive offices address
  • 801-708-6800 (other) — registrant's telephone number

FAQ

What is the purpose of this 8-K filing by Health Catalyst, Inc.?

This 8-K filing by Health Catalyst, Inc. is categorized under "Other Events" and "Financial Statements and Exhibits," indicating a routine update to disclose information that may not fit into other specific 8-K items but is deemed important for public record, such as confirming company details.

When was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024.

What is the current business address of Health Catalyst, Inc. as stated in the filing?

The current business address of Health Catalyst, Inc. is 10897 South River Front Parkway, #300, South Jordan, UT 84095.

What is the Commission File Number for Health Catalyst, Inc.?

The Commission File Number for Health Catalyst, Inc. is 001-38993.

Did Health Catalyst, Inc. report any change in its former name or address in this filing?

The filing states "Not Applicable" for "Former name or former address, if changed since last report," indicating no change in former name or address was reported in this specific 8-K.

Filing Stats: 973 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2024-01-08 16:01:31

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share HCAT The Nasdaq Global Select
  • $25 m — e 2024 Adjusted EBITDA of approximately $25 million, and a 2025 Adjusted EBITDA margi

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 8, 2024, Health Catalyst, Inc. (the Company) published its J.P. Morgan 2024 Healthcare Conference presentation (Presentation) on its investor relations website (https://ir.healthcatalyst.com/), including certain preliminary 2023 results and forward-looking commentary (Excerpt). Copies of the Presentation and Excerpt are filed hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference. "We are pleased to see that our preliminary results for 2023 Q4 and full-year 2023 Revenue and Adjusted EBITDA are coming in at or above the midpoint of our guidance range and we are also encouraged by our preliminary 2023 bookings results. We anticipate that our net new DOS Subscription Client performance for 2023 will be in line with our expectations and that our 2023 Dollar-Based Retention Rate will be approximately 100%, which is below our forecasted range of 102% to 110%. This estimated performance is primarily due to a timing delay with a few larger Tech-Enabled Managed Services (TEMS) expansion opportunities, which we still anticipate we will sign in the near future. We see continued evidence for optimism in our pipeline and momentum as we begin 2024." said Dan Burton, the Company's Chief Executive Officer. Turning to forward-looking commentary, Dan Burton added, "As we continue to focus on growth reacceleration, we anticipate improvement in 2024 net new DOS Subscription Client bookings and Dollar-Based Retention Rate metrics relative to 2023, including through continued improvement in the operating environment of our end market. Finally, we are pleased to share that based on continued profitability progress, we now anticipate 2024 Adjusted EBITDA of approximately $25 million, and a 2025 Adjusted EBITDA margin target of 10% or greater." The Company has not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable measure calculated in accordance with generally accepted accounting princ

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 , including statements concerning or relating to the Company's expectations regarding its operating performance, including its DOS Subscription Client bookings and Dollar-Based Retention Rate, and its financial performance, including Adjusted EBITDA and Adjusted EBITDA margin. Any forward-looking statements contained in this Current Report on Form 8-K are based upon the Company's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent the Company's expectations as of the date of this Current Report on Form 8-K, and involve risks, uncertainties, and assumptions. The actual results may differ materially from those anticipated in the forward-looking statements as a result of numerous factors, many of which are beyond the control of the Company, including changes under the Company's financial performance, including expectations regarding its results of operations, unexpected or otherwise unplanned events, and the risks and uncertainties disclosed in the Company's reports filed from time to time with the Securities and Exchange Commission, including its most recent Form 10K and any subsequent filings on Forms 10-Q or 8-K, available at www.sec.gov. Except as required by law, the Company does not intend to update any forward-looking statement contained in this Current Report on Form 8-K to reflect events or circumstances arising after the date hereof.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Presentation 99.2 Excerpt 104 Cover page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEALTH CATALYST, INC. Date: January 8, 2024 By: /s/ Bryan Hunt Bryan Hunt Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.